ClinicalTrials.gg
CompletedNCT05032560Updated Jan 26, 2023

Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

A Phase 1 interventional study of ABX464 and Placebo in Healthy Volunteers, sponsored by Abivax S.A.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Abivax S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The study consists of Part A, a randomized double-blind, single-ascending-dose study, and Part B, a randomized, double-blind, semi-sequential, escalating multiple-dose study, in healthy Japanese volunteers.

Read the detailed description

Part A includes the following two dose regimen groups:

  • 25 mg dose regimen group: ABX464 25 mg or placebo
  • 50 mg dose regimen group: ABX464 50 mg or placebo In each dose regimen group, 12 subjects will be randomly assigned, according to a 3:1 ratio, to receive either ABX464 (9 subjects) or its matching placebo (3 subjects).

Part B includes the following two dose regimen groups:

  • 25 mg dose regimen group: ABX464 25 mg or placebo for 28 days
  • 50 mg dose regimen group: ABX464 50 mg or placebo for 28 days

In each dose regimen group, 12 subjects will be randomly assigned, according to a 3:1 ratio, to receive either ABX464 (9 subjects) or its matching placebo (3 subjects).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male Japanese volunteers.
  2. 20 to 45 years old.
  3. Considered by the Investigator, as healthy based on history, physical examination, and complete laboratory evaluation (laboratory parameters should be within normal ranges of the study center's laboratory or considered not by the Investigator).
  4. Vital signs (supine blood pressure, resting pulse rate, body temperature) should be within normal ranges and no deviation from standard 12-lead (ECG) should be observed at screening.

    (BMI) should be between 18 (inclusive) and 27 kg/m² (inclusive).

  5. Non-smokers at enrolment.
  6. Subjects must understand, sign and date the written voluntary Form at the visit prior to any protocol-specific procedures.
  7. Able and willing to comply with study visits and procedures as per protocol.
  8. Males receiving the study treatment and their partners must agree to use a highly effective method during the study and for 6 months after the last dose of study drug. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, and vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over 1 month between menstruations) in a female partner of a male subject, confirmation of absence of pregnancy of the partner is required. Male subjects must not be planning pregnancy, should use a condom and must not donate sperm during the study and for 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Acute disease state (e.g., nausea, vomiting, diarrhea, or fever within a week) or chronic infectious disease (positive results for surface antigen [HBsAg], virus antibody, antigen/antibody, tuberculosis determined by QuantiFERON-TB Gold Plus test). Subjects who have positive hepatitis B core antibody [HBcAb] can be enrolled but must have an undetectable hepatitis B virus [HBV] viral load (HBV DNA test).
  2. Positive results for SARS-CoV-2 antigen determined by polymerase chain reaction method.
  3. History of recent grade 3 or 4 opportunistic infection or underlying conditions that may predispose them to grade 3 or grade 4 infection.
  4. History of cardiovascular, pulmonary, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematological, neurological, psychiatric, or systemic disease that could jeopardize the safety of the subject or the validity of the study results.
  5. Illicit drug or alcohol abuse, or dependence within a year.
  6. Blood donation within 3 months prior to screening.
  7. Use of any or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer.
  8. Use of any drugs (except topical ) within 3 months prior to first dose.
  9. Any history of to drugs.
  10. Any condition, which in the opinion of the Investigator, could compromise the subject's safety or adherence to the study protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    25 mg single dose

    Subject will receive a single oral dose of ABX464 25 mg or its matching placebo

    Drug: ABX464 · Drug: Placebo

  • Experimental
    50 mg single dose

    Subject will receive a single oral dose of ABX464 50 mg or its matching placebo

    Drug: ABX464 · Drug: Placebo

  • Experimental
    25 mg multiple dose

    Subject will receive a daily oral dose of ABX464 25 mg or its matching placebo for 28 days

    Drug: ABX464 · Drug: Placebo

  • Experimental
    50 mg mulptiple dose

    Subject will receive a daily oral dose of ABX464 50 mg or its matching placebo for 28 days

    Drug: ABX464 · Drug: Placebo

Interventions

  • DrugABX464

    Drug: ABX464 ABX464 is a new anti-inflammatory drug

  • DrugPlacebo

    Drug: Matching Placebo placebo matching with ABX464

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and SAEs

    number of incidences of all adverse events (AEs) (causally related and non-related) and SAEs, will be described further categorized by severity

    Time frame: 6 weeks

  2. incidence of treatment-emergent serious adverse events

    number of incidences of treatment-emergent serious adverse events will be described

    Time frame: 6 weeks

  3. incidence of treatment-emergent adverse events of special interest (AESIs).

    number of incidences of treatment-emergent adverse events of special interest (AESIs) will be described.

    Time frame: 6 weeks

  4. incidence of clinically significant laboratory abnormalities

    number of incidences of clinically significant laboratory abnormalities will be described

    Time frame: 6 weeks

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Cmax of ABX464 will be derived from the plasma concentrations

    Time frame: 42 days

  2. Area under the plasma concentration versus time curve (AUC)

    AUC of ABX464 will be derived from the plasma concentrations

    Time frame: 42 days

  3. Time to reach the maximum plasma concentration (tmax)

    Tmax of ABX464 will be derived from the plasma concentrations

    Time frame: 42 days

  4. miR124 level

    concentration of miR124 expression will be measured in blood

    Time frame: 42 days

07

Study locations

1 site
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka-shi, Osaka 532-0003, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Feb 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 2, 2021
StartActual
Sep 27, 2021
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05032560
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 27, 2021
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Last update
Jan 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion